Median Technologies (FR:ALMDT)
:ALMDT
Want to see FR:ALMDT full AI Analyst Report?
Top Page
Median Technologies
(ALMDT)
Select Model
Select Model
Rating:48Neutral
Price Target:
€5.50
▲(20.35% Upside)
Action:Reiterated
Date:04/30/26
The score is held down primarily by weak financial fundamentals—large ongoing losses, persistent cash burn, and negative equity—despite improving revenue growth. Technical indicators are moderately constructive (price above key moving averages and positive MACD), but valuation provides limited support given negative earnings and no dividend yield data.
Positive Factors
Improving Revenue Growth
Sustained revenue acceleration (noted +21.5% in 2025) indicates growing commercial traction for imaging analytics in trials. Over 2-6 months this trend supports larger deal flow and scale benefits, improving prospects for converting R&D momentum into repeatable service revenues.
Negative Factors
Persistent Cash Burn
Chronic negative operating cash flow implies the company must rely on external financing to fund operations. Over 2-6 months this reduces strategic flexibility, raises dilution and refinancing risks, and can constrain investment in product development or commercial expansion if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Revenue Growth
Sustained revenue acceleration (noted +21.5% in 2025) indicates growing commercial traction for imaging analytics in trials. Over 2-6 months this trend supports larger deal flow and scale benefits, improving prospects for converting R&D momentum into repeatable service revenues.
Read all positive factors
Median Technologies (ALMDT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€206.94M
Dividend YieldN/A
Average Volume (3M)465.96K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth1.79%
EPS Growth15.89%
CountryFR
Employees225
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.15
Shares Outstanding37,655,190
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.49
Revenue Forecast (FY)€26.53M
Median Technologies Business Overview & Revenue Model
Company Description
Median Technologies (ALMDT) is a leading company specializing in medical imaging and artificial intelligence solutions, primarily targeting the healthcare sector. The company focuses on enhancing the efficiency and effectiveness of cancer diagnosi...
How the Company Makes Money
Median Technologies primarily generates revenue by providing imaging analytics products and services to life-sciences customers (e.g., pharmaceutical and biotechnology companies) that run clinical trials. Key revenue streams typically include: (1)...
Median Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.36M | 22.95M | 22.23M | 23.67M | 20.55M |
| Gross Profit | -13.66M | -21.07M | -2.55M | 24.42M | 20.43M |
| EBITDA | -13.66M | -19.28M | -19.59M | -17.48M | -17.10M |
| Net Income | -34.07M | -25.24M | -22.98M | -20.21M | -19.29M |
Balance Sheet | |||||
| Total Assets | 35.87M | 24.37M | 35.94M | 34.75M | 49.39M |
| Cash, Cash Equivalents and Short-Term Investments | 18.41M | 8.29M | 19.63M | 21.67M | 39.25M |
| Total Debt | 21.76M | 29.44M | 23.01M | 18.15M | 16.52M |
| Total Liabilities | 71.02M | 58.34M | 46.23M | 42.01M | 44.45M |
| Stockholders Equity | -35.15M | -33.97M | -10.29M | -7.25M | 4.94M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -19.03M | -21.53M | -17.18M | -10.61M |
| Operating Cash Flow | -17.43M | -17.95M | -20.24M | -15.79M | -10.13M |
| Investing Cash Flow | -824.00K | -1.17M | -1.25M | -1.39M | -672.00K |
| Financing Cash Flow | 28.43M | 7.67M | 19.72M | -277.00K | 33.20M |
Median Technologies Technical Analysis
Positive
4.57
Price Trends
4.77
Positive
4.75
Positive
3.87
Positive
Market Momentum
0.14
Negative
70.26
Negative
75.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMDT, the sentiment is Positive. The current price of 4.57 is below the 20-day moving average (MA) of 4.99, below the 50-day MA of 4.77, and above the 200-day MA of 3.87, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 70.26 is Negative, neither overbought nor oversold. The STOCH value of 75.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALMDT.
Median Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | €45.66M | -1.03 | -14.58% | ― | 0.87% | 46.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €24.95M | -5.20 | -17.18% | ― | 138.92% | 11.14% | |
48 Neutral | €206.94M | -1.75 | 59.08% | ― | 1.79% | 15.89% | |
46 Neutral | €35.67M | -2.78 | 467.60% | ― | 42.86% | 13.93% |
* Healthcare Sector Average
FR:ALMDT
Median Technologies
5.50
3.27
146.09%
FR:ALTHE
Theraclion SA
0.49
0.20
71.23%
FR:ALNOV
Novacyt
0.63
0.16
33.26%
FR:ALDMS
Diagnostic Medical Systems
1.29
0.25
24.04%
FR:ALIKO
Ikonisys SA
1.58
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.